VLON
Vallon Pharmaceuticals, Inc. [VLON] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
VLON Stock Summary
In the News
VLON Financial details
Company Rating
-
Market Cap
5.39M
Income
-13.5M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
26 Jul 2023
P/E
-25.9
Forward P/E
-
PEG
3.08
P/S
-
P/B
5798.81
P/C
-
P/FCF
-0.75
Quick Ratio
3.15
Current Ratio
3.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.23
EPS next Y
-
EPS next Q
-
EPS this Y
-50.35%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-82.14%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-331%
ROE
-292%
ROC
-4.25%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.3803-0.4308
52W High
-
52W Low
-
RSI
-
Rel Volume
-
Avg Volume
-
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-1.14856
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
Company Profile
- Market Capitalization 5.39M
- Employee 2
- CEO Mr. David C. Baker
- Headquarters Philadelphia,PA,US
- IPO Date 2021-02-10
-
Website
https://www.vallon-pharma.com 
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
